Screener
Pulse Biosciences, Inc. PLSE Business Segments — Cross Platform Research And Engineering
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept plse:CrossPlatformResearchAndEngineering.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026288
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue | $434 | — | $835 | — |
| Adjusted cost of product revenue1 | 245 | — | 571 | — |
| Cross platform research and engineering2 | 6,078 | 4,585 | 11,258 | 8,535 |
| R&D manufacturing and engineering3 | 3,201 | 2,941 | 5,550 | 4,736 |
| Clinical and regulatory4 | 5,127 | 2,183 | 8,387 | 3,943 |
| General and administrative5 | 4,548 | 2,742 | 8,490 | 5,461 |
| Sales and marketing6 | 1,279 | 2,362 | 3,607 | 4,218 |
| Other segment items7 | 5,228 | 5,462 | 7,394 | 11,426 |
Document
FAQ
- What is Pulse Biosciences, Inc.'s business segments — cross platform research and engineering?
- Pulse Biosciences, Inc. (PLSE) reported business segments — cross platform research and engineering of $6.08M in Q2 2026.
- What does business segments — cross platform research and engineering mean?
- This captures the investment in research, development, and engineering activities aimed at advancing the company's proprietary technology platforms. It reflects the company's commitment to innovation and the long-term sustainability of its product pipeline.
Ask your AI about Pulse Biosciences, Inc.'s business segments — cross platform research and engineering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude